A practical reference on wound model: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
== Career == He joined the Department of Pharmacology of Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, on 14 April 1964 as Professor and Founder Chairman Department of Pharmacology. He served a period as Head Department of Pharmacology till 30 September 1985 and in view of his outstanding merits, he was re-employed by the University for the two years to 30 September 1987. Soon after retirement, he was selected as emeritus scientist of the ICMR, New Delhi, for a period from 1 September 1987, which he served till 14 September 1990. On 31 January 1991, the University appointed him as professor emeritus. In the university, he had also acted as Dean, Faculty of Medicine, In-charge, Animal House and on few occasions as acting Principal Ajmal Khan Tibbiya College and acting Vice Chancellor of the University. As a Professor Emeritus, he continued his active research in the Department of Pharmacology till late December 1994.
Techniques such as the controlled encapsulation of individual gas bubbles to create hollow nanoparticles for synthesizing microbubbles with specific contents are vital for drug delivery systems. Both silica and titanium-based microparticles are used as durable shells after using gas to increase the flow velocity of the aqueous phase. A higher flow velocity allows greater control over the thickness of the aqueous shells. The emerging versatility of nanoparticles can be seen in the delivery of particle-loaded microdroplets being utilized in depot injections for drug delivery rather than the typical approach of injecting drugs intravenously. This is possible due to the low thickness of the shells which typically are in the range of 1 to 50 μm. More recent advancements in microfluidic particles allowed the synthesis of nanometer sized particles from biologically derived polymers. Using specific flow-focusing multiphase designs that control flow rate and temperature, the size of nanoparticle formation can be controlled along with the concentration and configuration of the droplets. Another technique for creating particle-loaded microdroplets is the use of lipid-hydrogel nanoparticles that can be manipulated into more narrowly shaped droplets, which is useful when soft or brittle materials must be used. These soft materials are especially important in the production of powders.
== Peptide hormones and related substances == Certain peptide hormones increase bulk, strength, and oxygen-carrying red blood cells. Erythropoiesis-stimulating agents such as erythropoietin (EPO), darbepoetin (dEPO), hypoxia-inducible factor (HIF) stabilizers, methoxy polyethylene glycol-epoetin beta (CERA) and peginesatide (Hematide); growth hormone (hGH), insulin-like growth factors (IGF-1, etc.), fibroblast growth factors (FGFs), hepatocyte growth factors (HGF), mechano growth factors (MGFs), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), human chorionic gonadotropin (hcG, banned in men only), somatotrophin (growth hormone), insulins and corticotrophins, corticosteroid mimics, and their releasing factor, are banned. Also banned are any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularization, energy utilization, regenerative capacity or fiber type switching, and other substances with similar chemical structure and/or biological effects.
Sources: en.wikipedia.org
Sermorelin acetate (INNTooltip International Nonproprietary Name; brand names Geref, Gerel), also known as GHRH (1-29), is a peptide analogue of growth hormone-releasing hormone (GHRH) which is used as a diagnostic agent to assess growth hormone (GH) secretion for the purpose of diagnosing growth hormone deficiency. It is a 29-amino acid polypeptide representing the 1–29 fragment from endogenous human GHRH, thought to be the shortest fully functional fragment of GHRH. Sermorelin was approved by the US Food and Drug Administration (FDA) in 1997 for use as a treatment for children with growth hormone deficiency or growth failure. However, as of 2008, the manufacturer discontinued the production of Sermorelin for commercial reasons, and it is no longer available as an FDA-approved drug. Despite this, it may still be used in some off-label contexts or obtained through compounding pharmacies.
When the United States Navy ended Japan's Sakoku policy, and thus its isolation, the latter found itself defenseless against military pressures and economic exploitation by the Western powers. For Japan to emerge from the feudal period, it had to avoid the colonial fate of other Asian countries by establishing genuine national independence and equality. Following the María Luz Incident, Japan released the Chinese coolies from a western ship in 1872, after which the Qing imperial government of China gave thanks to Japan. However, tension soon rose between Qing China and Meiji Japan as a result of geopolitical tug-of-war for control and influence over the strategically vital Korean Peninsula. In 1884, pro-Japanese reformers in Korea, whom admired the successes of the Meiji Restoration and wanted to get rid of Korea's traditional subservience to an already weakened China after the Opium Wars, staged a brief coup d'état which triggered a clash with Qing troops stationed in Seoul who intervened to rescue the Korean king. In 1885, both nations signed an agreement to withdraw their troops from Korea and agreed to notify one another before sending military forces to the peninsula in the future. Tensions flared further in 1894 when Kim Ok-kyun, the pro-Japanese leader of the 1884 coup, was lured to Shanghai and assassinated, allegedly by Qing agents. The Japanese public was outraged, viewing this as a direct affront. At the same time, a massive peasant uprising broke out in Korea and the Korean king requested military aid from the Qing government to disperse the rebels.
Club, described the film as "boneheaded" and "a perfect hate-watch" noting that Macdonald "slaps together some cheap, quick-cut montages gesturing at the modern surveillance state" but lacks the "feel for the pace or tension needed to keep the energy up in a film like this," and commenting that "The extended workout, either shot so far away that it looks like stock footage or so tight that it loses all sense of context, is never any more exciting than watching Gadot lope on a treadmill." Dennis Harvey, in a similarly negative review for Variety, wrote that the film "lacks the strong suspense or novelty necessary to elevate an overfamiliar concept" and criticized the acting, saying "Nor is Gadot a performer inclined to lend much more than athleticism to a role that could use some warmth and idiosyncrasy to color its rather generic action-hero gist." In a review for TheWrap, William Bibbiani wrote, "The Runner isn't much of a thriller. It isn't much of a movie. It would, however, be a hilarious episode of Taskmaster."
=== Impacts of gender stereotypes in health and medicine === Gender stereotypes influence both diagnosis and treatment practices for men and women. Ancient theories, such as those of Hippocrates, perpetuated hierarchical models in which the female body was considered a deviation from the male norm—a view that persisted into the 19th century. Some diseases are underdiagnosed in one sex due to stereotypical associations. For instance, women are less frequently and less accurately diagnosed with myocardial infarction, despite an increase in incidence among women between 2008 and 2013 (+20%). Symptoms in women may differ from those in men and are less well-known or recognized. In 2015, cardiovascular disease accounted for 51% of deaths in women in Europe. Similar disparities exist in other conditions. Women with chronic obstructive pulmonary disease (COPD) are diagnosed later than men, even though prevalence is now similar. Women with autism spectrum disorders are often diagnosed late, which has been linked to significantly reduced life expectancy compared to non-autistic women. Strokes, more common among women, also have more severe outcomes in women but were less studied in female patients as of 2017. Conversely, some conditions such as osteoporosis are underdiagnosed in men, as the disease is often seen as predominantly affecting women. Despite this, men represent one-third of hip fractures and have a higher risk of complications.
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.